The clinical application of the first-class ANXA3 inhibitor SL-18 has not been addressed in clinical trials to date, and the validation of an ANXA3-specific inhibitor for in vivo use with meningioma cells remains pending. The gene discussed is ANXA3; the disease is meningioma.